| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CD20 |
| Uniprot No | P11836 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-297aa |
| 氨基酸序列 | MTTPRNSVNGTFPAEPMKGPIAMQSGPKPLFRRMSSLVGPTQSFFMRESK TLGAVQIMNGLFHIALGGLLMIPAGIYAPICVTVWYPLWGGIMYIISGSL LAATEKNSRKCLVKGKMIMNSLSLFAAISGMILSIMDILNIKISHFLKME SLNFIRAHTPYINIYNCEPANPSEKNSPSTQYCYSIQSLFLGILSVMLIF AFFQELVIAGIVENEWKRTCSRPKSNIVLLSAEEKKEQTIEIKEEVVGLT ETSSQPKNEEDIEIIPIQEEEEEETETNFPEPPQDQESSPIENDSSP |
| 预测分子量 | 58 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于CD20重组蛋白的文献概览(注：文献信息为模拟示例，实际引用请核实原始论文)：
---
1. **文献名称**：Structural basis of CD20 recognition by therapeutic antibodies rituximab and obinutuzumab
**作者**：Joseph G., et al.
**摘要**：通过冷冻电镜解析了CD20重组蛋白与单克隆抗体(如利妥昔单抗)的结合表位，揭示了其跨膜结构域与抗体相互作用的分子机制，为优化靶向治疗提供结构依据。
2. **文献名称**：Recombinant CD20 antigen expression in CHO cells for antibody binding analysis
**作者**：Zhang Y., et al.
**摘要**：报道了一种在CHO细胞中高效表达重组CD20蛋白的方法，并验证其与临床抗体的结合活性，为体外药物筛选及功能研究提供标准化抗原。
3. **文献名称**：Mechanisms of resistance to anti-CD20 monoclonal antibodies in B-cell malignancies
**作者**：Beers S.A., et al.
**摘要**：探讨了CD20重组蛋白的糖基化修饰及膜定位突变如何影响抗体结合效率，提出肿瘤细胞表面抗原密度降低是导致利妥昔单抗耐药的关键因素之一。
---
建议通过PubMed或Google Scholar搜索真实文献，关键词：**CD20 recombinant protein structure/therapy/mutation**。
CD20 is a cell surface protein predominantly expressed on B lymphocytes, playing a critical role in immune regulation and B-cell activation. First identified in the 1980s, it is encoded by the MS4A1 gene and features four transmembrane domains, forming a calcium-permeable ion channel involved in cellular signaling. Unlike many cell surface markers, CD20 lacks glycosylation sites, making its structure relatively simple and stable. Its expression is restricted to B cells from the pre-B cell stage to mature B cells but absent on plasma cells, positioning it as an ideal therapeutic target for B-cell malignancies and autoimmune disorders without compromising long-term immunity.
Recombinant CD20 protein is engineered using genetic technology, typically expressed in mammalian or insect cell systems to mimic its native conformation. This protein retains key epitopes recognized by therapeutic monoclonal antibodies (e.g., rituximab, obinutuzumab), enabling its use in drug development, mechanism studies, and diagnostic assays. Researchers employ CD20 recombinant proteins to investigate antibody binding kinetics, assess drug resistance mechanisms, and develop biosimilars. In diagnostics, it serves as a critical component in flow cytometry and ELISA to quantify anti-CD20 antibody levels in patient sera or assess CD20 expression patterns in hematological cancers.
The clinical significance of CD20 recombinant protein extends to personalized medicine, where it aids in predicting patient responses to anti-CD20 immunotherapies. Its role in advancing CAR-T cell therapy research has grown recently, particularly in optimizing chimeric antigen receptor designs. As B-cell-targeted therapies expand into autoimmune conditions like multiple sclerosis and rheumatoid arthritis, recombinant CD20 remains indispensable for both basic research and translational applications.
×
